CellCentric announced the completion of an oversubscribed $220 million Series D financing to support pivotal clinical trials of inobrodib, the company’s first-in-class oral p300/CBP inhibitor for the treatment of multiple myeloma.
The financing was led by Venrock Healthcare Capital Partners and included participation from Fidelity Management & Research Company, Sofinnova Partners, HBM Healthcare, and existing investors, including RA Capital Management, Forbion, Pfizer, Avego BioScience Capital, and American Cancer Society BrightEdge.
According to the company, the proceeds will support continued enrollment in the Phase 2 DOMMINO-1 study in the United Kingdom and the United States, along with the planned initiation of the global Phase 3 DOMMINO-2 trial during the second half of 2026. The funding will also support the expansion of inobrodib into additional combination and maintenance treatment settings.
CellCentric is developing inobrodib as a first-in-class oral therapy targeting p300/CBP inhibition for patients with relapsed or refractory multiple myeloma. The company said the drug has been evaluated in more than 500 patients across hematologic malignancies and solid tumors.
Phase 2 dose-optimization data presented at the American Society of Hematology meeting in December 2025 showed that 20 mg inobrodib combined with pomalidomide and dexamethasone demonstrated at least a 2-fold increase in response rates compared with historical alternative therapies among heavily pretreated relapsed or refractory multiple myeloma patients.
CellCentric said inobrodib is also being evaluated in combination with bispecific therapies including elranatamab and teclistamab, as well as in maintenance treatment settings. The FDA previously granted Fast Track and orphan drug designations to inobrodib for relapsed or refractory multiple myeloma.
CellCentric is a privately held biotechnology company headquartered in Cambridge, England, with operations in Boston.
KEY QUOTES:
“We are thrilled to have the support of top-tier investors who believe in inobrodib’s potential to address a critical need in multiple myeloma, notably after bispecific T cell engager or anti-BCMA therapies. This is a significant and growing unmet need. Inobrodib is a new modality and a potential fresh option for patients that is orally administered. In combination with pomalidomide and dexamethasone as InoPd, we have demonstrated deep responses in heavily pretreated relapsed or refractory multiple myeloma patients. Fueled by this funding, we are well positioned to complete registration enabling studies for the all-oral triplet and advance our progress toward delivering a transformative treatment.”
Will West, Ph.D., CEO, CellCentric
“What stands out with inobrodib is the consistency of clinical activity alongside a manageable safety profile in a heavily pretreated population. An oral drug with a novel, additive approach could play an important role in later-line therapy, as well as across the treatment landscape in multiple myeloma. We are excited to support its advancement into pivotal studies.”
Ken Greenberg, M.D., Partner, Venrock
